Vann, K. R., Sharma, R., Hsu, C.-C., Devoucoux, M., Tencer, A. H., Zeng, L., Lin, K., Zhu, L., Li, Q., Lachance, C., Ospina, R. R., Tong, Q., Cheung, K. L., Yang, S., Biswas, S., Xuan, H., Gatchalian, J., Alamillo, L., Wang, J., … Kutateladze, T. G. (2025). Structure-function relationship of ASH1L and histone H3K36 and H3K4 methylation. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-57556-5

Karger, L. M., Webb, B. D., Edelmann, L., Liao, J., & Mehta, L. (2024). Familial RPL26 Variant Causing Congenital Anomalies Without Hematological Features of Diamond Blackfan Anemia. American Journal of Medical Genetics Part A. Portico. https://doi.org/10.1002/ajmg.a.63954

Shipman, G. A., Padilla, R., Horth, C., Hu, B., Bareke, E., Vitorino, F. N., Gongora, J. M., Garcia, B. A., Lu, C., & Majewski, J. (2024). Systematic perturbations of SETD2, NSD1, NSD2, NSD3, and ASH1L reveal their distinct contributions to H3K36 methylation. Genome Biology, 25(1). https://doi.org/10.1186/s13059-024-03415-3

Pottinger, T. D., Motelow, J. E., Povysil, G., Moreno, C. A. M., Ren, Z., Phatnani, H., Harms, M. B., Kwan, J., Sareen, D., Wang, H.-I., Broach, J. R., Simmons, Z., Arcila-Londono, X., Parrott, S., Lee, E. B., Parrott, S., Deerlin, V. M. V., Fraenkel, E., … Ostrow, L. W. (2024). Rare variant analyses validate known ALS genes in a multi-ethnic population and identifies ANTXR2 as a candidate in PLS. BMC Genomics, 25(1). https://doi.org/10.1186/s12864-024-10538-1

Nakagawa, S., Carnevali, D., Tan, X., Alvarez, M. J., Parfitt, D.-E., Di Vicino, U., Arumugam, K., Shin, W., Aranda, S., Normanno, D., Sebastian-Perez, R., Cannatá, C., Cortes, P., Neguembor, M. V., Shen, M. M., Califano, A., & Cosma, M. P. (2024). The Wnt-dependent master regulator NKX1-2 controls mouse pre-implantation development. Stem Cell Reports, 19(5), 689–709. https://doi.org/10.1016/j.stemcr.2024.04.004

Zhang, F., Sahu, V., Peng, K., Wang, Y., Li, T., Bala, P., Aitymbayev, D., Sahgal, P., Schaefer, A., Der, C. J., Ryeom, S., Yoon, S., Sethi, N., Bass, A. J., & Zhang, H. (2024). Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer. Gut, 73(8), 1280–1291. https://doi.org/10.1136/gutjnl-2023-329686

De Simone, P., Bal, E., Holmes, A., Hilton, L., Basso, K., Soni, R. K., Morin, R., Dalla-Favera, R., & Pasqualucci, L. (2023). BTG2 Super-Enhancer Mutations Disrupt TFAP4 Binding and Deregulate BTG2 Expression in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 523–523. https://doi.org/10.1182/blood-2023-190230

Shi, A., Ali, A. M., Cann, G., Shaknovich, R., Venn, O., Raza, A., & Liu, Q. (2023). Methylation Biology of a Blood-Based MDS Risk Stratification Test. Blood, 142(Supplement 1), 4599–4599. https://doi.org/10.1182/blood-2023-180256

Piorczynski, T. B., Ryu, Y. K., Pazos, M., Huang, W., Tolu, S. S., Estrella, B., & Amengual, J. E. (2023). Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 4391–4391. https://doi.org/10.1182/blood-2023-179271

Cherng, H.-J. J., Yang, X., Yancey, R., Gordillo, C. A., Piorczynski, T. B., Chan, H. T., Ofori, K. N., Bhagat, G., Califano, A., Pro, B., Booher, K., Amengual, J. E., Reshef, R., & Sina, A. A. I. (2023). Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes. Blood, 142(Supplement 1), 4371–4371. https://doi.org/10.1182/blood-2023-178376

Pazos, M., Estrella, B., Piorczynski, T. B., Tolu, S. S., Huang, W., Ryu, Y. K., & Amengual, J. E. (2023). First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL. Blood, 142(Supplement 1), 4184–4184. https://doi.org/10.1182/blood-2023-186639

Salles, G., Park, S. I., Phillips, T. J., Amengual, J. E., Andorsky, D. J., Campbell, P., McKay, P., Leonard, J. P., Chen, Y., Chen, J., Bannerji, R., Kapopara, A., Szanto, A., & Morschhauser, F. (2023). Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up. Blood, 142(Supplement 1), 3035–3035. https://doi.org/10.1182/blood-2023-179910

Amengual, J. E., Shyr, Y., Durecki, D., Beumer, J. H., Mansukhani, M. M., Williams, M., Kelleher, N., Cherng, H., Pro, B., Schwartz, G. K., LoRusso, P., & Piekarz, R. (2023). ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA. Hematological Oncology, 41(S2), 833–834. Portico. https://doi.org/10.1002/hon.3166_ot14

Pal, I., Scotto, L., Sabzevari, A., Kinahan, C., Fox, T. E., Feith, D. J., Marchi, E., Loughran, T. P., & O’Connor, O. A. (2023). Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma. Hematological Oncology, 41(S2), 313–314. Portico. https://doi.org/10.1002/hon.3164_220

Saito, Y., Yin, D., Kubota, N., Wang, X., Filliol, A., Remotti, H., Nair, A., Fazlollahi, L., Hoshida, Y., Tabas, I., Wangensteen, K. J., & Schwabe, R. F. (2023). A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. Gastroenterology, 164(7), 1279–1292. https://doi.org/10.1053/j.gastro.2023.02.043

Vlasevska, S., Garcia-Ibanez, L., Duval, R., Holmes, A. B., Jahan, R., Cai, B., Kim, A., Mo, T., Basso, K., Soni, R. K., Bhagat, G., Dalla-Favera, R., & Pasqualucci, L. (2023). KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells. Proceedings of the National Academy of Sciences, 120(11). https://doi.org/10.1073/pnas.2218330120

de Prisco, N., Ford, C., Elrod, N. D., Lee, W., Tang, L. C., Huang, K.-L., Lin, A., Ji, P., Jonnakuti, V. S., Boyle, L., Cabaj, M., Botta, S., Õunap, K., Reinson, K., Wojcik, M. H., Rosenfeld, J. A., Bi, W., Tveten, K., Prescott, T., … Gennarino, V. A. (2023). Alternative polyadenylation alters protein dosage by switching between intronic and 3′UTR sites. Science Advances, 9(7). https://doi.org/10.1126/sciadv.ade4814

Savari, O., Febres‐Aldana, C., Chang, J. C., Fanaroff, R. E., Ventura, K., Bodd, F., Paik, P., Vundavalli, M., Saqi, A., Askin, F. B., Travis, W. D., & Rekhtman, N. (2022). Non‐small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours. Histopathology, 82(2), 242–253. Portico. https://doi.org/10.1111/his.14801

Ding, L., Gao, L., Lee, H., & Goodman, J. (2023). 3050 – AN EPITRANSCRIPTOMIC PROGRAM DISTINGUISHES HEMATOPOIETIC STEM CELL NICHE GENERATION FROM MAINTENANCE. Experimental Hematology, 124, S75. https://doi.org/10.1016/j.exphem.2023.06.157

Kim, M., Singh, M., Lee, B.-K., Hibbs, M., Richardson, K., Ellies, L., Wintle, L., Stuart, L. M., Wang, J. Y., Voon, D. C., Blancafort, P., Wang, J., Kim, J., Leedman, P. J., & Woo, A. J. (2022). A MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancer. Oncogenesis, 11(1). https://doi.org/10.1038/s41389-022-00435-1

Ballout, F., Lu, H., Chen, L., Sriramajayam, K., Que, J., Meng, Z., Wang, T. C., Giordano, S., Zaika, A., McDonald, O., Peng, D., & El-Rifai, W. (2022). APE1 redox function is required for activation of Yes-associated protein 1 under reflux conditions in Barrett’s-associated esophageal adenocarcinomas. Journal of Experimental & Clinical Cancer Research, 41(1). https://doi.org/10.1186/s13046-022-02472-5

Lue, J. K., Stevens, D. A., Williams, M. E., Westin, J., Ewesuedo, R., McDonald, A., Agarwal, S., Henrick, P., Perea, R., & Gollob, J. (2022). Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 140(Supplement 1), 12143–12144. https://doi.org/10.1182/blood-2022-170151

Coutinho, D. F., Mundi, P. S., Marks, L. J., Burke, C., Ortiz, M. V., Diolaiti, D., Bird, L., Vallance, K. L., Ibáñez, G., You, D., Long, M., Rosales, N., Grunn, A., Ndengu, A., Siddiquee, A., Gaviria, E. S., Rainey, A. R., Fazlollahi, L., Hosoi, H., … Dela Cruz, F. S. (2022). Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors. Med, 3(11), 774-791.e7. https://doi.org/10.1016/j.medj.2022.09.002

Shen, Y., Singh, J., Sah, B., Chen, Z., Ha, W., Henzler, C., Su, T., Xie, L., Deng, Y., Li, G., Guo, H., Hibshoosh, H., & Liu, L. (2022). The Histone Demethylase HR Suppresses Breast Cancer Development through Enhanced CELF2 Tumor Suppressor Activity. Cancers, 14(19), 4648. https://doi.org/10.3390/cancers14194648

Li, Y., Goldberg, E. M., Chen, X., Xu, X., McGuire, J. T., Leuzzi, G., Karagiannis, D., Tate, T., Farhangdoost, N., Horth, C., Dai, E., Li, Z., Zhang, Z., Izar, B., Que, J., Ciccia, A., Majewski, J., Yoon, A. J., Ailles, L., … Lu, C. (2022). Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Molecular Cell, 82(20), 3901-3918.e7. https://doi.org/10.1016/j.molcel.2022.09.007

Johnson, M. L., Rodon, J., Aljumaily, R., Villalona-Calero, M., Borazanci, E., Pishvaian, M., Turk, A., Carvajal, R. D., Mantia, C., Giaccone, G., Mounir, Z., Patel, A., Maurer, M., Neilan, C., Rajendran, D., Ganesan, U., Hinkle, J., & Tolcher, A. W. (2022). 492TiP A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion. Annals of Oncology, 33, S766–S767. https://doi.org/10.1016/j.annonc.2022.07.620

van der Sluijs, P. J., Joosten, M., Alby, C., Attié-Bitach, T., Gilmore, K., Dubourg, C., Fradin, M., Wang, T., Kurtz-Nelson, E. C., Ahlers, K. P., Arts, P., Barnett, C. P., Ashfaq, M., Baban, A., van den Born, M., Borrie, S., Busa, T., Byrne, A., Carriero, M., … Santen, G. W. E. (2022). Discovering a new part of the phenotypic spectrum of Coffin-Siris syndrome in a fetal cohort. Genetics in Medicine, 24(8), 1753–1760. https://doi.org/10.1016/j.gim.2022.04.010

Canto, L. M., da Silva, J. M., Castelo-Branco, P. V., da Silva, I. M., Nogueira, L., Fonseca-Alves, C. E., Khayat, A., Birbrair, A., & Pereira, S. R. (2022). Mutational Signature and Integrative Genomic Analysis of Human Papillomavirus-Associated Penile Squamous Cell Carcinomas from Latin American Patients. Cancers, 14(14), 3514. https://doi.org/10.3390/cancers14143514

Chen, H., Hu, B., Horth, C., Bareke, E., Rosenbaum, P., Kwon, S. Y., Sirois, J., Weinberg, D. N., Robison, F. M., Garcia, B. A., Lu, C., Pastor, W. A., & Majewski, J. (2022). H3K36 dimethylation shapes the epigenetic interaction landscape by directing repressive chromatin modifications in embryonic stem cells. Genome Research. https://doi.org/10.1101/gr.276383.121

Antoszewski, M., Fournier, N., Ruiz Buendía, G. A., Lourenco, J., Liu, Y., Sugrue, T., Dubey, C., Nkosi, M., Pritchard, C. E. J., Huijbers, I. J., Segat, G. C., Alonso-Moreno, S., Serracanta, E., Belver, L., Ferrando, A. A., Ciriello, G., Weng, A. P., Koch, U., & Radtke, F. (2022). Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL. Blood, 139(16), 2483–2498. https://doi.org/10.1182/blood.2021012077

Zhang, W., Ruan, X., Li, Y., Zhi, J., Hu, L., Hou, X., Shi, X., Wang, X., Wang, J., Ma, W., Gu, P., Zheng, X., & Gao, M. (2022). KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway. Theranostics, 12(4), 1500–1517. https://doi.org/10.7150/thno.66142

Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320